Actemra
My Prescription
Payment
Select pharmacy
$1,220.40
$30.00 due at pharmacy
$1,220.40 - $30.00 = $1,190.40
$1,190.40 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
AlbertsonsPowered by$1,220.40
Print or send this coupon to your phone
AlbertsonsPowered byAbout Actemra
Drug Details
Tocilizumab, known by the brand name Actemra, is a medication used to manage several inflammatory conditions in both adults and children. It is primarily prescribed for moderate-to-severe rheumatoid arthritis, giant cell arteritis, and systemic sclerosis-associated interstitial lung disease in adults, as well as polyarticular and systemic juvenile idiopathic arthritis in children aged 2 years and older. Additionally, it is used for cytokine release syndrome in children and adults, and for hospitalized adults with COVID-19 who are on corticosteroids and require oxygen support or mechanical ventilation. Tocilizumab functions as an interleukin-6 (IL-6) receptor antagonist. It works by blocking IL-6, a protein produced by the immune system that leads to inflammation and fever. By inhibiting this protein, tocilizumab helps to decrease inflammation and swelling, thereby alleviating symptoms associated with these conditions. The medication is administered via injection, either intravenously or subcutaneously, with the frequency of dosage varying based on the condition being treated. While tocilizumab can be highly effective, it is important to be aware of potential side effects, such as an increased risk of infections and headaches. Always consult with a healthcare professional before starting any new medication to ensure it is suitable for your specific health needs.
Price history for Actemra
1 Syringe, 0.9ML of 162MG/0.9ML
Average retail price for Actemra
Average SaveHealth price for Actemra
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Actemra dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 0.9ML of 162MG/0.9ML | 1 Syringe | $1,220.40 | $1,220.40 |
| 0.9ML of 162MG/0.9ML | 2 Syringes | $2,432.80 | $1,216.40 |
| 0.9ML of 162MG/0.9ML | 3 Syringes | $3,645.21 | $1,215.07 |
Actemra FAQs
Actemra, also known as tocilizumab, is a medication that works by inhibiting the activity of interleukin-6 (IL-6), a protein in the body that plays a role in inflammation. By blocking IL-6, Actemra helps reduce inflammation and is used to treat conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome. It can help alleviate symptoms like joint pain and swelling, and improve physical function in patients with these conditions.
Actemra and Humira are not the same. Actemra (tocilizumab) and Humira (adalimumab) are both medications used to treat certain autoimmune conditions, but they work differently. Actemra is an interleukin-6 (IL-6) receptor antagonist, while Humira is a tumor necrosis factor (TNF) inhibitor. They are used to treat conditions like rheumatoid arthritis, but the choice between them depends on the specific needs and medical history of the patient.
Actemra (tocilizumab) is considered a medication that requires careful monitoring due to potential risks and side effects. It is important for patients to be under the supervision of a healthcare provider while using Actemra, as it can affect the immune system and increase the risk of infections. Regular blood tests and monitoring for signs of infection or other adverse effects are typically recommended.
Yes, Actemra (tocilizumab) is an anti-inflammatory medication. It is a monoclonal antibody that works by inhibiting the interleukin-6 (IL-6) receptor, which plays a role in the inflammatory process. It is used to treat conditions such as rheumatoid arthritis and other inflammatory disorders.
Actemra (tocilizumab) carries a black box warning for the risk of serious infections. These infections can include tuberculosis, bacterial, invasive fungal, viral, and other opportunistic infections that may lead to hospitalization or death. It is important for healthcare providers to screen patients for latent tuberculosis before starting treatment and to monitor for signs and symptoms of infection during therapy.